Cutaneous, mucocutaneous and visceral leishmaniasis in Sweden from 1996–2016: a retrospective study of clinical characteristics, treatments and outcomes

Abstract

BackgroundLeishmaniasis is a neglected and poorly reported parasitic infection transmitted by sand flies in tropical and subtropical regions. Knowledge about leishmaniasis has become important in non-endemic countries due to increased migration and travel. Few studies of the clinical management of cutaneous, mucocutaneous and visceral leishmaniasis in non-endemic regions have been published to date. In this study, we aimed to evaluate patient characteristics, clinical manifestations and treatments of leishmaniasis in Sweden, over a 20-year period.MethodsA retrospective observational nationwide study was performed using medical records of patients diagnosed with leishmaniasis in Sweden from 1996 to 2016. Cases with culture and polymerase chain reaction verified leishmaniasis were identified at the Public Health Agency of Sweden.ResultsIn total, 165 cases of leishmaniasis were diagnosed from 1996 to 2016. Medical records from 156 patients (95%) were available for review and included in the study. Cutaneous leishmaniasis was the dominant manifestation (n = 149, 96%), and in 66 patients (44%) cutaneous leishmaniasis was due to Leishmania tropica. Other manifestations were mucocutaneous (n = 4, 3%), visceral (n = 2, 1%) and post-kala-azar dermal leishmaniasis (n = 1, 1%). During this time period, the number of cases increased, especially after 2013. Most patients (n = 81, 52%) were migrants who were infected in their countries of origin (from 2013 to 2016, mainly Syria or Afghanistan). Other groups were Swedish tourists (25%) and returning workers (13%). The time from collection of the diagnostic sample to the start of treatment was less than one month in 81 (66%) patients and under three months in 124 patients (96%). Among the 149 patients with cutaneous leishmaniasis, 125 patients received antileishmanial treatment, and in 88 of these patients (70%) cure was achieved, regardless of treatment.ConclusionsThe number of leishmaniasis cases diagnosed in Sweden increased between 1996 and 2016, mainly in migrants from endemic countries. Although leishmaniasis is a rare disease in Sweden, patients appear to be diagnosed early and treated according to current European guidelines, resulting in an overall high cure rate.Electronic supplementary materialThe online version of this article (10.1186/s12879-018-3539-1) contains supplementary material, which is available to authorized users.

Cutaneous leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre for tropical diseases

“…An increase in cases has also been reported by the GeoSentinel Surveillance Network, as well as in a recent retrospective observational study in Sweden. 8,15 In our study, patients with cutaneous leishmaniasis who were exposed in New World regions were more likely to travel for tourism, particularly to Costa Rica and Mexico. In Central America, Costa Rica reports the highest burden of cutaneous leishmaniasis, with an estimated annual incidence of 3500 to 5700 cases.…”

Effect of immunosuppressants on the parasite load developed in, and immune response to, visceral leishmaniasis: A comparative study in a mouse model

“…Indeed, HIV-associated immunosuppression has been identified as a major emerging challenge in the control of VL [5]. However, an increase in cases of VL has also been detected among recipients of solid organ transplants [7,8] and patients receiving immunosuppressants to treat autoimmune diseases such as rheumatoid arthritis, lupus erythematous and inflammatory bowel disease [9,10]. Ever more frequently used in these contexts, these drugs may increase the number of people susceptible to Leishmania infection as well as condition the severity of disease.…”

GIS-Based Risk Mapping of Cutaneous Leishmaniasis: A Survey in an Endemic Area of Central Iran

“…A common estimate of the worldwide incidence reported 1 to 2 million clinical new cases a year and the risk of disease is about 350 million and have 20,000-40,000 deaths causes each year. Dispite of new diagnosis and treatments of leishmaniasis, but it is now considered as a serious public health problem particularly in developing countries including Iran and has an economic burden on health resources (Cardoso, et al 2019;Mandal, et al 2018;Glans, et al 2018). Leishmaniasis has been reported as one of the most important neglected tropical diseases.…”